CSM is using the SOPHiA DDM™ Platform to
expand its next-generation sequencing (NGS) offerings
BOSTON and ROLLE, Switzerland, July 13,
2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native software company and a leader in data-driven
medicine, today announced Gruppo Centro Servizi Medici (CSM),
one of the largest centralized laboratories in Italy, is live on SOPHiA GENETICS technology.
CSM has implemented the SOPHiA DDM™ Platform to help expand its
current next-generation sequencing (NGS) offerings and advance its
research of hereditary cancer and homologous recombination
deficiency (HRD).
CSM, which is a consortium that brings together numerous
laboratories throughout Sicily,
conducts more than one million exams each year and offers roughly
1,500 different types of tests to best serve the population of
Italy. With the SOPHiA DDM™
Platform, CSM will enhance its NGS offerings, providing specialized
testing that furthers its ability to detect and categorize various
hereditary cancers and aid clinical researchers in identifying
genomic profiles that may be more receptive to certain
therapies.
The volume of data that results from NGS can be robust and
complex to analyze. The SOPHiA DDM™ Platform is a cloud-based
platform that uses Artificial Intelligence (AI) with patented
technologies to analyze and interpret NGS data. In addition,
the SOPHiA DDM™ Platform will aid CSM in creating a more efficient
bioinformatics workflow. Collectively, the SOPHiA GENETICS
technology has been designed to make it easier for customers like
CSM to combine speed and accuracy when processing NGS tests, which
is imperative when analyzing hereditary cancers and identifying
HRD-positive tumors.
With the SOPHiA GENETICS technology, CSM will have in-house
ownership of their genomic databases shared across their access
points. This, combined with faster interpretation of data, is
expected to increase the speed at which CSM delivers
results.
"It is our goal to democratize data-driven medicine, and the
enhanced testing offered by CSM will help enable that in
Italy," said Kevin Puylaert,
Managing Director, EMEA, SOPHiA GENETICS. "By using the SOPHiA DDM™
Platform, CSM will have unified data across all access points,
increasing the ease with which these sites can share data,
communicate and deliver genomic analyses."
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on Twitter, LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains
statements that constitute forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations and financial position, business strategy,
products, and technology, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management's beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-gruppo-centro-servizi-medici-csm-is-live-on-the-sophia-ddm-platform-301876315.html
SOURCE SOPHiA GENETICS